Roche’s Evrysdi (risdiplam) is the market leader among the drugs for spinal muscular atrophy (SMA). Biogen’s Spinraza ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products ...

Sales growth of Biogen’s spinal muscular atrophy drug, Spinraza, in the United States is likely to have been hurt by decreased demand amid competitive pressure. In ex-U.S. markets, Spinraza ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of ...

Biogen (NASDAQ:BIIB – Free Report ... The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for ...

But Spinraza's $381.4 million sales missed an estimate of $430.5 million. Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Also Read: Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate Rare disease revenue increased 10% year over year (up 10% CC) to $495 million. Spinraza’s ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...